Literature DB >> 13678790

Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-).

Fakhrul Ahsan1, John J Arnold, Tianzhi Yang, Elias Meezan, Erik M Schwiebert, Dennis J Pillion.   

Abstract

The permeability of human bronchial epithelial cells (16HBE14o(-)) to radiolabelled insulin ([125I]insulin) formulated in the absence or presence of two different saccharide-containing permeability enhancers was investigated. In the absence of either enhancer, mannitol permeability and transepithelial electrical resistance (R(TE)) remained essentially unaffected for the duration of a 2-h experiment. Addition of either 0.125% tetradecylmaltoside (TDM) or 1% dimethyl-beta-cyclodextrin (DMBCD) to the apical surface of cells resulted in increased mannitol permeability and decreased R(TE), suggesting a loosening of cellular tight junctions and a concomitant increase in paracellular movement. Addition of [125I]insulin to the apical side of 16HBE14o(-) cells in the absence or presence of 1% DMBCD resulted in little or no [125I]insulin movement to the basolateral chamber or degradation in the apical chamber. However, in the presence of 0.125% TDM, the amount of intact [125I]insulin remaining in the apical chamber was substantially decreased, while [125I]insulin and 125I-labeled fragments were recovered on the basolateral side of the cells after 2 h. These findings provide evidence that the loosening of the tight junctions between cells achieved with DMBCD is not sufficient to stimulate transepithelial insulin movement, whereas exposure to 0.125% TDM causes an increase in [125I]insulin permeation and degradation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678790     DOI: 10.1016/s0928-0987(03)00163-5

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Hearing Loss and Otopathology Following Systemic and Intracerebroventricular Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin.

Authors:  Scott Cronin; Austin Lin; Kelsey Thompson; Mark Hoenerhoff; R Keith Duncan
Journal:  J Assoc Res Otolaryngol       Date:  2015-06-09

2.  Pulmonary delivery of low molecular weight heparins.

Authors:  Tianzhi Yang; Fatima Mustafa; Shuhua Bai; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

3.  Nasal absorption of mixtures of fast-acting and long-acting insulins.

Authors:  Dennis J Pillion; Michael D Fyrberg; Elias Meezan
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

4.  Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes.

Authors:  Pedro P G Guimaraes; Mingchee Tan; Tuomas Tammela; Katherine Wu; Amanda Chung; Matthias Oberli; Karin Wang; Roman Spektor; Rachel S Riley; Celso T R Viana; Tyler Jacks; Robert Langer; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-02       Impact factor: 9.776

5.  Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies.

Authors:  Tianzhi Yang; Alamdar Hussain; Jennifer Paulson; Thomas J Abbruscato; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.